mSphere · 2022 · 13 citations · 51 references
Life SciencesBiochemistryMicrobiologyAntimicrobial ResistanceDrug DiscoveryMycologyAntifungal AgentsAntifungal ResistanceAntifungal TherapyAntimicrobial PeptidesFungal PathogenesisMechanisms Of Antimicrobial ResistanceAntibacterial PeptidesAntifungal PeptidesAntifungal Resistance MechanismsAntimicrobial Peptide ActivityCandida Albicans InfectionFungal Cell MembraneNew Antifungal AgentsPeptide Resistance Mechanisms
Fungal infections with the opportunistic human pathogen C. albicans are associated with high mortality rates in immunocompromised patients. This is partly due to the yeast's ability to rapidly develop resistance toward currently available antifungals. Small, cationic, membrane-active peptides are promising compounds to fight against resistance development, as many of them effectuate rapid fungal cell death. This fast killing is believed to hamper the development of resistance, as the fungi do not have sufficient time to adapt to the antifungal compound. We previously reported that the synthetic variant of the amphibian TB peptide, TB_KKG6K, rapidly kills C. albicans. In the current study, the mechanism of action of the TB analog was investigated. We show that this TB analog is membrane-active and impairs cell membrane function, highlighting its potential to be developed as an attractive alternative anti-C. albicans therapeutic that may hinder the development of resistance.
51
Torsten Koburger, N.-O. Hübner, Michael Braun et al. · Journal of Antimicrobial Chemotherapy · 2010 · 374 citations · Full text
Medicine, Pharmacology, Surgery +13